NonExomics, Inc is a scientists-led company that has pioneered the discovery process of the new wave of targets from the so-called Dark Genome. Over the last 8 years, we have meticulously developed AI-based algorithms deployed on the patient data at a population scale, to discover over 250,000 new proteins and investigated their disruptions in over 1365 human diseases. We have performed extensive in silico and experimental validation on these new targets to develop them as diagnostics and therapeutics.

Our target portfolio serves as a parallel universe in drug discovery that is ripe to be challenged by the available therapeutic modalities in various diseases.



We welcome opportunities to collaborate with other partners in challenging these newly-found genes using small molecules, antisense oligos, antibodies, gene therapy, etc.